Search results for "Interstitial lung disease"
showing 9 items of 39 documents
Drug-induced infiltrative lung disease
2009
International audience; Because the lung manifestations of drugs may be highly variable, a high index of suspicion is required. Both current and past drug intake should be carefully evaluated in any patient with infiltrative lung disease. Drug-induced infiltrative lung disease may manifest as variable clinical radiological patterns, including subacute or chronic interstitial pneumonia, pulmonary fibrosis, eosinophilic pneumonia (presenting as Loffler syndrome, or chronic or acute eosinophilic pneumonia), organising pneumonia, diffuse alveolar haemorrhage, acute respiratory distress syndrome, pulmonary oedema, lipoid pneumonia, alveolar proteinosis or sarcoidosis. A variety of drugs have bee…
IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease
2022
ObjectiveSystemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis. Our aim was to test whether both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared to SSc patients without ILD and healthy controls.MethodsSerum levels of IL-13 and IL-33 were measured in 30 SSc patients with diffuse disease and 30 healthy controls by enzyme-linked immunosorbent assay. The extent of p…
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis
2013
Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…
Iatrogenic pulmonary lesions.
2018
Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
2016
Background: Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc) up to two-third of the cases, representing the main cause of death in these patients. Assessment of lung involvement by HRCT and close monitoring of lung function are mandatory. At present no serologic biomarkers are validated for the assessment for lung damage in SSc. The current study was designed to test the hypothesis that the levels of surfactant are altered in SSc compared to healthy controls. To this aim serum levels of SP-A (Surfactant Protein A) and SP-D (Surfactant Protein-D) in serum were assessed. Methods: We enrolled 12 consecutive patients (M/F: 2/10) affected by scleroderma referred…
Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD)
2015
Objectives: To determine the prevalence of SAS in patients with ILD and its clinical characteristics, evolution and specific manifestations linked to each antisynthetase antibodies and highlight the need for its screening in ILD. Methods: Retrospective analysis of patients registered in the last two years in our ILD unit, determining antisynthetase antibodies and analyzing clinical, radiological, functional data and illness evolution. Results: 119 ILD patients were included, 10.9% had antisynthetase antibodies, the most prevalent were Jo-1 (46.1%) and PL-12 (38.5%). In PL-12 patients inicial and respiratory syntoms were predominant, whereas in the Jo-1 patients were more frequent extrapulmo…
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
2019
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…
THU0366 SYSTEMATIC CORONARY RISK EVALUATION (SCORE) MISCLASSIFIES CARDIOVASCULAR RISK IN ANTISYNTHETASE SYNDROME: RESULTS OF THE PILOT MULTICENTRIC S…
2020
Background:Antisynthetase Syndrom (ASyS) is an autoimmune overlap disease characterized by antiaminoacyl-tRNA-synthetase (anti-ARS) antibodies and the classic triad of arthritis, myositis and interstitial lung disease (ILD) (1). Markers of cardiovascular (CV) or cerebrovascular (CVB) risk have never been examined in ASyS.Objectives:Aim of this study (RIsk of CARdiovascular Disease in ASyS: RI.CAR.D.A.) was to test the ability of an established traditional CV risk prediction score (Systematic Coronary Risk Evaluation-SCORE) and its EULAR modified version (mSCORE) to identify ASyS patients at high CV risk. Moreover, we sought to examine for the first time associations of CV surrogate markers …
Neonatal Respiratory Insufficiency Caused by an (Homozygous) ABCA3-Stop Mutation: a Systematic Evaluation of Therapeutic Options
2014
Background Autosomal recessive ABCA3 (ATP-binding cassette protein A3) gene mutations have been associated with neonatal respiratory distress and pediatric interstitial lung disease. The clinical course of the disease depends on the underlying mutations. Therefore, knowledge of course, symptoms and treatment of the disease is important. Patient and methods A term newborn suffered from progressive respiratory insufficiency, which led to death at the age of 4.8 months. The girl developed interstitial lung disease. Infections as well as structural and functional disorders of the lung were systematically excluded. A homozygous c.4681C > T (Arg 1561 Stop) mutation of the ABCA3 gene was identifie…